Umut Mousa

Umut Mousa

Auto-generated profile, based on publicly available information

Umut Mousa

Department of Endocrinology and Metabolism, Baskent University Faculty of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2006 in Lung Cancer
Verified
Journal Article
Closed access
PDF file
GUGüngör Utkan
Güngör Utkan
ABAbdullah Büyükçelik
Abdullah Büyükçelik
BYBülent Yalçın
Bülent Yalçın
HAHakan Akbulut
Hakan Akbulut
ADAhmet Demirkazık
Ahmet Demirkazık
FIFikri İçli
Fikri İçli

23 January 2018 in Medical Principles and Practice
Verified
Journal Article
Open access
PDF file
CDCanan Demir
Canan Demir
CACuneyd Anil
Cuneyd Anil
YBYusuf Bozkus
Yusuf Bozkus
UMUmut Mousa
Umut Mousa
AKAltug Kut
Altug Kut
NTNeslihan B. Tutuncu
Neslihan B. Tutuncu
Objective: The objective of this study was to assess the antiproliferative pleiotropic effects of statins on thyroid function, volume, and nodularity. Subjects and Methods: One hundred and six hyperlipidemic patients were included in this prospective study. The 69 patients in the statin groups received atorvastatin (16 received 10 mg and 18 received 20 mg) or rosuvastatin (20 received 10 mg and 15 received 20 mg). The 37 patients in the control group, assessed as not requiring drugs, made only lifestyle changes. Upon admission and after 6 months, all patients were evaluated by ultrasonography as well as for lipid variables (total cholesterol, high- and low-density lipoprotein cholesterol, and triglycerides) and thyroid function and structure. Results: After 6 months, no differences in thyroid function, thyroid volume, the number of thyroid nodules, or nodule size were observed in the statin and control groups. In a subgroup analysis, total thyroid volume had decreased more in patients receiving 20 mg of rosuvastatin than that in the control group (p < 0.05). Maximum nodule size had decreased more in those receiving 10 mg of rosuvastatin (p < 0.05). Conclusions: Our results suggest an association between rosuvastatin treatment and smaller thyroid volume and maximum nodule diameter; this could be attributable to the antiproliferative effects of statin therapy on the thyroid.

18 November 2011 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
UMUmut Mousa
Umut Mousa
AGAlptekin Gursoy
Alptekin Gursoy
HOHandan Ozdemir
Handan Ozdemir
GMGokhan Moray
Gokhan Moray

2 April 2015 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
AKA. Kut
A. Kut
HKH. Kalli
H. Kalli
CAC. Anil
C. Anil
UMU. Mousa
U. Mousa
AGA. Gursoy
A. Gursoy

1 January 2018 in Acta Endocrinologica (Bucharest)
Verified
Journal Article
Closed access
UMU Mousa
U Mousa
Context. Previous studies have associated overt/subclinical hypothyroidism and obesity but have failed to confirm a causative relationship between them. Confusion is even more for subjects with Hashimoto's Thyroiditis (HT). Objective. In this study, we aimed to evaluate the fat distribution and metabolic profile of subjects with euthyroid HT as well as to establish an appropriate cut-off level of TSH for the development of metabolic syndrome (Mets) in both groups. Patients and Methods. All subjects were euthyroid whether under levothyroxine replacement or not. We recruited 301 volunteers (99 with HT and 202 without thyroid autoimmunity). Together with some metabolic variables, we measured the waist circumference, hip circumference, neck circumference manually; the total body fat with a body composition analyzer; and the visceral fat/ trunk fat percentage via abdominal bioelectrical impedance analysis. Results. A significant positive correlation was established between TSH levels and insulin, fasting plasma glucose, HOMA-IR and body mass index (r=0.28; p<0.001; r=0.27; p<0.05: r=0.32; p<0.001: r=0.13; p0.05). The prevalence of Mets was similar when HT subjects using levothyroxine or HT subjects with accompanying thyroid nodules were taken into consideration. Similarly, anthropometric and metabolic parameters were similar in both the HT group and the control group. We were unable to establish the TSH cut-off level by ROC analysis with desired sensitivity and specificity (AUC: 0.563 with 95% C.I. p=0.35; standard error 0.76). Conclusions. Although weight gain is frequently encountered in subjects with HT, such subjects with thyroid function tests in the euthyroid range have a similar prevalence of Mets and similar metabolic and anthropometric measurements compared to subjects without autoimmunity.

25 July 2012 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
UMUmut Mousa
Umut Mousa
HOHandan Onur
Handan Onur
GUGungor Utkan
Gungor Utkan